Relations of Biomarkers Representing Distinct Biological Pathways to Left Ventricular Geometry

Overview

Journal Circulation

Specialty Cardiology & Vascular Diseases

Date 2008 Nov 13

PMID 19001021

Citations 32

Authors

Raghava S Velagaleti

Philimon Gona

Daniel Levy

Jayashri Aragam

Martin G Larson

Geoffrey H Tofler

Wolfgang Lieb

Thomas J Wang

Emelia J Benjamin

Ramachandran S Vasan

Affiliations

Soon will be listed here.

Abstract

Background: Several biological pathways are activated concomitantly during left ventricular (LV) remodeling. However, the relative contribution of circulating biomarkers representing these distinct pathways to LV geometry is unclear.

Methods And Results: We evaluated 2119 Framingham Offspring Study participants (mean age, 57 years; 57% women) who underwent measurements of biomarkers of inflammation (C-reactive protein), hemostasis (fibrinogen and plasminogen activator inhibitor-1), neurohormonal activation (B-type natriuretic peptide), and renin-angiotensin-aldosterone system (aldosterone and renin modeled as a ratio [ARR]) and echocardiography at a routine examination. LV geometry was defined on the basis of sex-specific distributions of LV mass (LVM) and relative wall thickness (RWT): normal (LVM and RWT <80th percentile), concentric remodeling (LVM <80th percentile but RWT >or=80th percentile), eccentric hypertrophy (LVM >or=80th percentile but RWT <80th percentile), and concentric hypertrophy (LVM and RWT >or=80th percentile). We related the biomarker panel to LV geometry using polytomous logistic regression adjusting for clinical covariates and used backwards elimination to identify a parsimonious set of biomarkers associated with LV geometry. Modeled individually, C-reactive protein, fibrinogen, plasminogen activator inhibitor-1, and ARR were related to LV geometry (P<0.01). In multivariable analyses, the biomarker panel was significantly related to altered LV geometry (P<0.0001). On backwards elimination, logARR alone was significantly and positively associated with eccentric (odds ratio per SD increment, 1.20; 95% confidence interval, 1.05 to 1.37) and concentric LV hypertrophy (odds ratio per SD increment, 1.29; 95% confidence interval, 1.06 to 1.58).

Conclusions: Our cross-sectional observations on a large community-based sample identified ARR as a key correlate of concentric and eccentric LV hypertrophy, consistent with a major role for the renin-angiotensin-aldosterone system in LV remodeling.

Citing Articles

Characterizing the Origins of Primary Aldosteronism.

Brown J, Honzel B, Tsai L, Milks J, Neibuhr Y, Neibuhr Y Hypertension. 2024; 82(2):306-318.

PMID: 39660429 PMC: 11735322. DOI: 10.1161/HYPERTENSIONAHA.124.24153.

Successful treatment of resistant hypertension and severe complications in a 63-year-old man with primary aldosteronism without adrenalectomy: A case report.

Wang A, Ma Q, Mbikyo M, Miao L, Cui N, Fu H Heliyon. 2024; 10(13):e33688.

PMID: 39044991 PMC: 11263627. DOI: 10.1016/j.heliyon.2024.e33688.

Aldosterone Effect on Cardiac Structure and Function.

Al-Hashedi E, Abdu F Curr Cardiol Rev. 2024; 20(4):e290224227534.

PMID: 38425104 PMC: 11327832. DOI: 10.2174/011573403X281390240219063817.

Serum aldosterone effect on left ventricular structure and diastolic function in essential hypertension.

Al-Hashedi E, Zhao X, Mohammed A, Juvenal H, Yu J J Clin Hypertens (Greenwich). 2022; 25(2):213-222.

PMID: 36585812 PMC: 9903192. DOI: 10.1111/jch.14612.

Left Ventricular Hypertrophy Geometry and Vascular Calcification Co-Modify the Risk of Cardiovascular Mortality in Patients with End-Stage Kidney Disease: A Retrospective Cohort Study.

Chao C, Liao M, Wu C J Atheroscler Thromb. 2022; 30(9):1242-1254.

PMID: 36567124 PMC: 10499460. DOI: 10.5551/jat.63870.

References

Kannel W, Feinleib M, MCNAMARA P, Garrison R, CASTELLI W . An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979; 110(3):281-90. DOI: 10.1093/oxfordjournals.aje.a112813. View

Shigematsu Y, Hamada M, Mukai M, Matsuoka H, Sumimoto T, Hiwada K . Clinical evidence for an association between left ventricular geometric adaptation and extracardiac target organ damage in essential hypertension. J Hypertens. 1995; 13(1):155-60. View

Conen D, Zeller A, Pfisterer M, Martina B . Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension. Am J Cardiol. 2006; 97(2):249-52. DOI: 10.1016/j.amjcard.2005.08.028. View

Sundstrom J, Sullivan L, Selhub J, Benjamin E, DAgostino R, Jacques P . Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. Eur Heart J. 2004; 25(6):523-30. DOI: 10.1016/j.ehj.2004.01.008. View

Gardin J, McClelland R, Kitzman D, Lima J, BOMMER W, KLOPFENSTEIN H . M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol. 2001; 87(9):1051-7. DOI: 10.1016/s0002-9149(01)01460-6. View

Ingelsson E, Pencina M, Tofler G, Benjamin E, Lanier K, Jacques P . Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 2007; 116(9):984-92. DOI: 10.1161/CIRCULATIONAHA.107.708537. View

Bloor C, Nimmo L, McKirnan M, Zhang Y, WHITE F . Increased gene expression of plasminogen activators and inhibitors in left ventricular hypertrophy. Mol Cell Biochem. 1997; 176(1-2):265-71. View

Doi Y, Kiyohara Y, Kubo M, Ninomiya T, Wakugawa Y, Yonemoto K . Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care. 2005; 28(10):2497-500. DOI: 10.2337/diacare.28.10.2497. View

Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips R, Roniker B . Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003; 108(15):1831-8. DOI: 10.1161/01.CIR.0000091405.00772.6E. View

10.

Nilsson T, Boman K, Jansson J, Thogersen A, Berggren M, Broberg A . Comparison of soluble thrombomodulin, von Willebrand factor, tPA/PAI-1 complex, and high-sensitivity CRP concentrations in serum, EDTA plasma, citrated plasma, and acidified citrated plasma (Stabilyte) stored at -70 degrees C for 8-11 years. Thromb Res. 2005; 116(3):249-54. DOI: 10.1016/j.thromres.2004.12.005. View

11.

Brilla C . Renin-angiotensin system mediated mechanisms: cardioreparation and cardioprotection. Heart. 2000; 84 Suppl 1:i18-9:discussion i50. PMC: 1766536. DOI: 10.1136/heart.84.suppl_1.i18. View

12.

Devereux R, Alonso D, Lutas E, Gottlieb G, Campo E, Sachs I . Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57(6):450-8. DOI: 10.1016/0002-9149(86)90771-x. View

13.

Woodhams B, Girardot O, Blanco M, Colesse G, Gourmelin Y . Stability of coagulation proteins in frozen plasma. Blood Coagul Fibrinolysis. 2001; 12(4):229-36. DOI: 10.1097/00001721-200106000-00002. View

14.

Kaptoge S, White I, Thompson S, Wood A, Lewington S, Lowe G . Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies.... Am J Epidemiol. 2007; 166(8):867-79. DOI: 10.1093/aje/kwm191. View

15.

Wachtell K, Dahlof B, Rokkedal J, Papademetriou V, Nieminen M, Smith G . Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Am Heart J. 2002; 144(6):1057-64. DOI: 10.1067/mhj.2002.126113. View

16.

Iwashima Y, Horio T, Kuroda S, Takishita S, Kawano Y . Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension. Hypertens Res. 2002; 25(1):49-56. DOI: 10.1291/hypres.25.49. View

17.

Lewis M, Callas P, Jenny N, Tracy R . Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost. 2002; 86(6):1495-500. View

18.

Sato A, Saruta T . Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 2001; 29(1):13-21. DOI: 10.1177/147323000102900103. View

19.

Vasan R, Evans J, Benjamin E, Levy D, Larson M, Sundstrom J . Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension. 2004; 43(5):957-62. DOI: 10.1161/01.HYP.0000124251.06056.8e. View

20.

Nakahara T, Takata Y, Hirayama Y, Asano K, Adachi H, Shiokawa G . Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide. Circ J. 2007; 71(5):716-21. DOI: 10.1253/circj.71.716. View